

Flora Sam

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1649666/flora-sam-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71
papers

12,487
citations

37
h-index

75
g-index

75
ext. papers

14,372
ext. citations

6.6
avg, IF

5.61
L-index

#	Paper	IF	Citations
71	A misdirected conundrum in translational HFpEF research.. <i>Journal of Molecular and Cellular Cardiology</i> , 2022 ,	5.8	
70	Skeletal muscle (dys)function in heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2021 , 36, 219-226	2.1	0
69	Reply to letter by Hou et al., Doxycycline ameliorates autophagy by inhibiting p38 MAPK in cardiac myocytes. <i>International Journal of Cardiology</i> , 2021 , 331, 212	3.2	
68	Reply to letter by Ye et al., blocking lncRNA H19/miR-194-5p/SIRT1 axis in cardiac myocyte is responsible for doxycycline inhibiting autophagy. <i>International Journal of Cardiology</i> , 2021 , 331, 213	3.2	0
67	Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction: Insights Into the Cardiorenal Syndrome. <i>Circulation: Heart Failure</i> , 2021 , 14, e008372	7.6	1
66	Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1166-1187	15.1	17
65	Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. <i>Circulation</i> , 2020 , 141, 1001-1026	16.7	95
64	Doxycycline decreases amyloidogenic light chain-induced autophagy in isolated primary cardiac myocytes. <i>International Journal of Cardiology</i> , 2020 , 321, 133-136	3.2	7
63	Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. <i>Scientific Reports</i> , 2019 , 9, 8552	4.9	15
62	Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2019 , 124, 122-130	3	5
61	Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 110	5.4	16
60	Cardiac macrophages promote diastolic dysfunction. <i>Journal of Experimental Medicine</i> , 2018 , 215, 423-440	16.6	182
59	Reply: Diet-Induced Obesity HFpEF Murine Models. <i>JACC Basic To Translational Science</i> , 2018 , 3, 158-159	8.7	
58	Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition". <i>JACC Basic To Translational Science</i> , 2017 , 2, 770-789	8.7	96
57	Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	40
56	Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study. <i>Circulation</i> , 2016 , 133, 282-90	16.7	157
55	Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. <i>Circulation: Heart Failure</i> , 2016 , 9, e002724	7.6	38

54	Monocyte and macrophage contributions to cardiac remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 93, 149-55	5.8	161
53	Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2016 , 1, 207-221	8.7	27
52	Delayed myocardial recovery in peripartum cardiomyopathy. <i>International Journal of Cardiology</i> , 2015 , 184, 310-312	3.2	3
51	Withdrawal of heart failure medications in peripartum cardiomyopathy after myocardial recovery. <i>International Journal of Cardiology</i> , 2015 , 190, 212-3	3.2	0
50	Obesity and Cardiovascular Disease 2014 , 285-294		
49	Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. <i>American Journal of Cardiology</i> , 2014 , 113, 691-6	3	39
48	Non-invasive imaging for cardiac amyloidosis - delaying the obvious?. <i>International Journal of Cardiology</i> , 2014 , 177, e87-9	3.2	1
47	Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 976-85	7.6	41
46	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1495-1539	15.1	233
45	New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 516-27	3.3	24
44	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i> , 2013 , 128, e240-327	16.7	1927
43	Mitochondrial encoded NADH dehydrogenase 5 (MT-ND5) gene point mutation presents as late onset cardiomyopathy. <i>International Journal of Cardiology</i> , 2013 , 167, e143-5	3.2	7
42	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2013 , 62, e147-239	15.1	4318
41	Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. <i>Journal of the American Heart Association</i> , 2013 , 2, e005868	6	17
40	2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i> , 2013 , 128, 1810-52	16.7	2321
39	Adiponectin modulates oxidative stress-induced autophagy in cardiomyocytes. <i>PLoS ONE</i> , 2013 , 8, e68697	3.7	61
38	Interferon- β ablation exacerbates myocardial hypertrophy in diastolic heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 303, H587-96	5.2	45
37	Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment. <i>Heart Failure Clinics</i> , 2011 , 7, 385-93	3.3	12

36	Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. <i>American Journal of Pathology</i> , 2011 , 178, 61-8	5.8	37
35	Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. <i>International Journal of Hypertension</i> , 2011 , 2011, 346985	2.4	23
34	Adiponectin in cardiovascular inflammation and obesity. <i>International Journal of Inflammation</i> , 2011 , 2011, 376909	6.4	68
33	Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling. <i>Circulation: Heart Failure</i> , 2011 , 4, 621-7	7.6	50
32	Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy. <i>Journal of Biological Chemistry</i> , 2011 , 286, 9840-8	5.4	32
31	Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, E899-906	11.5	99
30	Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 301, H984-93	5.2	79
29	Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2010 , 3, 168-77	6.7	187
28	Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. <i>Endocrinology</i> , 2010 , 151, 322-34.8		65
27	What can adiponectin say about left ventricular function?. <i>Heart</i> , 2010 , 96, 331-2	5.1	13
26	Serial troponin-I measurement as a diagnostic and therapeutic tool in chronic myocarditis. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 820-2	5.8	0
25	Determinants of adiponectin levels in patients with chronic systolic heart failure. <i>American Journal of Cardiology</i> , 2010 , 105, 1147-52	3	20
24	Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. <i>Journal of Biological Chemistry</i> , 2009 , 284, 35839-49	5.4	119
23	A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. <i>Circulation</i> , 2009 , 119, 2058-68	16.7	86
22	Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. <i>Hypertension</i> , 2009 , 54, 583-90	8.5	28
21	Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 296, H1983-93	5.2	30
20	Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. <i>Circulation: Heart Failure</i> , 2008 , 1, 249-57	7.6	40
19	Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure. <i>American Journal of Cardiology</i> , 2007 , 100, 285-90	3	16

18	Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. <i>Hypertension</i> , 2007 , 50, 489-96	8.5	46
17	Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. <i>Hypertension</i> , 2007 , 49, 1084-94	8.5	51
16	Adiponectin protects against the development of systolic dysfunction following myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 42, 1065-74	5.8	192
15	Predictors of improved left ventricular systolic function in an urban cardiomyopathy program. <i>American Journal of Cardiology</i> , 2006 , 98, 1622-6	3	3
14	Digesting the remodeled heart: role of lysosomal cysteine proteases in heart failure. <i>Hypertension</i> , 2006 , 48, 830-1	8.5	18
13	The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. <i>Journal of Cardiac Failure</i> , 2006 , 12, 122-7	3.3	55
12	Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. <i>Journal of Cardiac Failure</i> , 2005 , 11, 473-80	3.3	159
11	Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. <i>Circulation</i> , 2005 , 111, 420-7	16.7	155
10	Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. <i>Hypertension</i> , 2005 , 46, 555-61	8.5	116
9	Aldosterone and cardiovascular remodelling: focus on myocardial failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004 , 5, 3-13	3	12
8	Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. <i>Hypertension</i> , 2004 , 43, 957-62	8.5	115
7	Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. <i>American Journal of Hypertension</i> , 2004 , 17, 188-93	2.3	58
6	Myocardial nitric oxide in cardiac remodeling 2003 , 155-170		
5	Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. <i>Circulation Research</i> , 2001 , 88, 1080-7	15.7	247
4	Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. <i>Circulation Research</i> , 2001 , 89, 351-6	15.7	139
3	ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 280, H984-91	5.2	46
2	Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000 , 279, H422-8	5.2	147
1	Left-ventricular structural and functional remodeling in the mouse after myocardial infarction: assessment with the isovolumetrically-contracting Langendorff heart. <i>Journal of Molecular and Cellular Cardiology</i> , 1998 , 30, 1443-7	5.8	27

